Integra LifeSciences (NASDAQ:IART) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Integra LifeSciences (NASDAQ:IART) posted its quarterly earnings results on Tuesday. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.12, Zacks reports. The business had revenue of $442.65 million for the quarter, compared to analysts’ expectations of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.89 earnings per share.

Integra LifeSciences Stock Down 2.8 %

Shares of NASDAQ IART opened at $24.04 on Wednesday. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $44.69. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock has a market cap of $1.85 billion, a P/E ratio of -265.97, a P/E/G ratio of 0.73 and a beta of 1.17. The firm has a 50 day moving average price of $23.71 and a 200 day moving average price of $21.83.

Insiders Place Their Bets

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. This represents a 2.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on IART. Morgan Stanley began coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price on the stock. Citigroup increased their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.